Funding accelerates Ultromics' work to close one of medicine's most pervasive health-equity gaps: heart failure with preserved ejection fraction (HFpEF), a condition that affects millions of women worldwide yet often goes unrecognized

资金加速了Ultromics的工作，以缩小医学中最普遍的健康公平差距之一：射血分数保留的心力衰竭（HFpEF），这种疾病影响全球数百万女性，但常常未被识别。

Built and validated on diverse, outcomes-based data, Ultromics' AI turns a routine heart ultrasound into an objective diagnostic tool, helping clinicians identify early heart failure before symptoms are dismissed or missed

基于多样化、以结果为导向的数据构建和验证，Ultromics 的人工智能将常规心脏超声转变为客观的诊断工具，帮助临床医生在症状被忽视或遗漏之前识别早期心力衰竭。

OXFORD, England

牛津，英格兰

,

，

Dec. 17, 2025

2025年12月17日

/PRNewswire/ --

/PRNewswire/ --

Ultromics

超声心动图智能分析系统

, a pioneer in AI-driven cardiology solutions, today announced an investment from the American Heart Association's

，一家人工智能驱动的心脏病学解决方案的先驱，今天宣布获得了美国心脏协会的投资。

Go Red for Women Venture Fund

女性红计划风险基金

, a fund within American Heart Association Ventures (the venture capital program of the American Heart Association). The funding accelerates Ultromics' mission to make early identification of heart failure a standard part of cardiac care, expanding access to its FDA-cleared AI platform already used in leading U.S.

，该基金隶属于美国心脏协会风险投资公司（美国心脏协会的风投项目）。这笔资金加速了Ultromics的使命，即让心力衰竭的早期识别成为心脏护理的标准部分，并扩大其已经在美国主要医疗机构中使用的、获得FDA批准的AI平台的访问范围。

hospitals and reimbursed across public and private payers..

医院并由公共和私人支付方报销。

Continue Reading

继续阅读

Ultromics Secures Strategic Investment from the American Heart Association’s Go Red for Women Venture Fund™

Ultromics获得美国心脏协会Go Red for Women风险基金的战略投资

Ultromics' technology helps clinicians detect heart failure with preserved ejection fraction (HFpEF), a condition that disproportionately affects women and is too often missed until it's advanced. The investment—the second by the Go Red for Women Venture Fund—reflects a shared commitment to advancing innovation and improving outcomes for women..

Ultromics的技术帮助临床医生检测射血分数保留的心力衰竭（HFpEF），这种病症对女性的影响尤为严重，且往往在病情恶化之前难以发现。这项投资——Go Red for Women风险基金的第二笔投资——体现了共同致力于推动创新和改善女性健康结果的承诺。

Heart failure remains one of the

心力衰竭仍然是其中之一

leading causes of death for women

女性死亡的主要原因

, yet symptoms of HFpEF like fatigue, shortness of breath, and swelling are

，然而 HFpEF 的症状如疲劳、呼吸急促和肿胀是

often dismissed or misattributed

常常被忽视或误认

to aging, weight or other conditions. Studies show that

针对衰老、体重或其他状况。研究表明

women are twice as likely as men

女性的可能性是男性的两倍

to develop this form of heart failure, and that

发展成这种心力衰竭，并且

up to 64% of cases go undiagnosed

高达64%的病例未被诊断出来

in clinical practice. The result is a diagnostic blind spot that leaves many women without access to new, life-prolonging therapies now proven to reduce hospitalizations and improve survival.

在临床实践中，其结果是一个诊断盲点，导致许多女性无法获得现已证明可减少住院和提高生存率的、新的延长生命的疗法。

'Closing the diagnostic gap by recognizing disease before irreversible damage occurs is critical to improving health for women—and everyone,' said Tracy Warren, Senior Managing Director, Go Red for Women Venture Fund. 'We are gratified to see technologies, such as this one, that are accepted by leading institutions as advances in the field of cardiovascular diagnostics.

“通过在不可逆损害发生之前识别疾病来缩小诊断差距，这对改善女性乃至所有人的健康至关重要，”Go Red for Women风险基金高级董事总经理Tracy Warren表示。“我们很高兴看到像这样的技术被领先机构视为心血管诊断领域的进步。”

That's the kind of progress our fund was created to accelerate.'.

这正是我们的基金旨在加速的进展。

Ultromics' AI helps reveal what even skilled cardiologists can't always detect: the subtle changes in a cardiac ultrasound that mark the earliest stages of heart failure.

Ultromics的人工智能有助于揭示即使是熟练的心脏病专家也不总是能检测到的东西：标志着心力衰竭最早期阶段的心脏超声波的细微变化。

EchoGo® Heart

EchoGo® 心脏

Failure

失败

is built on one of the largest echocardiography datasets in the world, representing a diverse population of patients. Validated on real patient outcomes instead of subjective human labels, EchoGo analyzes routine ultrasound scans to quantify heart function and identify patterns that signal HFpEF. By validating against diverse outcomes data, the system has demonstrated consistent performance across gender, age, and risk groups, seeing early signs of disease even when symptoms are not obvious.

建立在世界上最大的超声心动图数据集之一的基础上，代表了多样化的患者群体。EchoGo 不依赖主观的人工标签，而是通过真实患者的治疗结果进行验证，分析常规超声扫描以量化心脏功能并识别提示 HFpEF 的模式。通过对多样化结果数据的验证，该系统在性别、年龄和风险群体中表现出一致的性能，甚至能够在症状不明显时发现疾病的早期迹象。

The results give physicians an objective, accurate report within the same workflow hospitals already use..

结果会在医院已使用的相同工作流程内为医生提供一份客观、准确的报告。

'Heart failure with preserved ejection fraction is one of the most complex and overlooked diseases in cardiology. For too long, clinicians have been expected to diagnose it using tools that weren't built to detect it, and as a result, many patients are identified too late,' said Ross Upton, PhD, CEO and Founder of Ultromics.

“射血分数保留的心力衰竭是心脏病学中最复杂且被忽视的疾病之一。长期以来，临床医生一直被期望使用并非为检测该病而设计的工具来诊断它，导致许多患者确诊得太晚，”Ultromics首席执行官兼创始人罗斯·厄普顿博士说道。

'By augmenting physicians' decision making with EchoGo, we can help them recognize disease at an earlier stage and treat it more effectively.'.

“通过使用EchoGo增强医生的决策能力，我们可以帮助他们更早地识别疾病并更有效地治疗。”

Used by hospitals across the U.S. and U.K., Ultromics' AI has already analyzed more than 430,000 echocardiograms, making it one of most utilized technologies of its kind. In clinical studies, current HFpEF clinical risk scores were non-diagnostic in 60% of patients vs EchoGo Heart Failure which reached a diagnostic decision in 93% of patients, while demonstrating high accuracy and consistency across diverse patient populations.

美国和英国的医院都在使用 Ultromics 的人工智能技术，该技术已经分析了超过 430,000 份超声心动图，成为同类技术中应用最广泛的之一。在临床研究中，目前的 HFpEF 临床风险评分在 60% 的患者中无法诊断，而 EchoGo Heart Failure 在 93% 的患者中能够做出诊断决策，同时在不同患者群体中展现出高准确性和一致性。

The technology's validation across multiple leading research institutions confirms that AI validated on patient outcomes can deliver stronger, fairer results in everyday cardiac care..

该技术在多个领先研究机构的验证表明，基于患者结果验证的人工智能可以在日常心脏护理中提供更强、更公平的结果。

About Ultromics

关于Ultromics

Founded out of the University of Oxford, Ultromics is redefining cardiovascular care with FDA-cleared, AI-powered tools that enhance echocardiographic diagnosis. Built in partnership with the NHS and Mayo Clinic, its EchoGo® platform helps clinicians detect complex heart diseases earlier and more accurately—using nothing more than a standard ultrasound scan.

源于牛津大学的Ultromics正在通过获得FDA批准的、由人工智能驱动的工具重新定义心血管护理，这些工具增强了超声心动图诊断能力。其EchoGo®平台与英国国家医疗服务体系（NHS）和梅奥诊所合作开发，帮助临床医生更早、更准确地检测复杂的心脏病，且仅需使用标准的超声波扫描即可。

Ultromics is backed by leading investors and U.S. healthcare systems and is on a mission to transform how heart disease is diagnosed and treated. For more, visit .

Ultromics 得到了领先投资者和美国医疗系统的支持，致力于改变心脏病的诊断和治疗方法。欲了解更多信息，请访问 。

www.ultromics.com

www.ultromics.com

.

。

Photo -

照片 -

https://mma.prnewswire.com/media/2847646/Ultromics_Photo.jpg

https://mma.prnewswire.com/media/2847646/Ultromics_Photo.jpg

SOURCE Ultromics

来源：Ultromics

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示